Histogen Inc. (HSTO): Price and Financial Metrics

Histogen Inc. (HSTO): $1.25

0.05 (+4.50%)

POWR Rating

Component Grades













Add HSTO to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where HSTO ranks best; there it ranks ahead of 98.09% of US stocks.
  • The strongest trend for HSTO is in Value, which has been heading up over the past 51 days.
  • HSTO's current lowest rank is in the Stability metric (where it is better than 2.77% of US stocks).

HSTO Stock Summary

  • With a market capitalization of $4,997,958, HISTOGEN INC has a greater market value than only 1.76% of US stocks.
  • Revenue growth over the past 12 months for HISTOGEN INC comes in at 265.21%, a number that bests 97.07% of the US stocks we're tracking.
  • HISTOGEN INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -87.96%, greater than the shareholder yield of only 6.81% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to HISTOGEN INC, a group of peers worth examining would be NOVN, AYRO, AIM, NAVB, and CRNT.
  • HSTO's SEC filings can be seen here. And to visit HISTOGEN INC's official web site, go to www.histogeninc.com.

HSTO Valuation Summary

  • HSTO's price/sales ratio is 1.3; this is 72.34% lower than that of the median Healthcare stock.
  • HSTO's price/earnings ratio has moved up 19 over the prior 118 months.

Below are key valuation metrics over time for HSTO.

Stock Date P/S P/B P/E EV/EBIT
HSTO 2023-03-24 1.3 0.3 -0.5 0.3
HSTO 2023-03-23 1.1 0.3 -0.4 0.3
HSTO 2023-03-22 1.3 0.3 -0.5 0.3
HSTO 2023-03-21 1.5 0.4 -0.5 0.2
HSTO 2023-03-20 1.6 0.4 -0.5 0.2
HSTO 2023-03-17 1.5 0.4 -0.5 0.2

HSTO Growth Metrics

    The year over year price growth rate now stands at -81.55%.
  • The 2 year revenue growth rate now stands at -70.35%.
  • Its 4 year net cashflow from operations growth rate is now at -161.39%.
Over the past 30 months, HSTO's revenue has gone down $10,923,000.

The table below shows HSTO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.77 -9.962 -11.28
2022-06-30 4.356 -11.399 -11.525
2022-03-31 4.356 -11.265 -11.353
2021-12-31 1.032 -14.532 -14.95
2021-09-30 1.505 -15.888 -15.323
2021-06-30 1.409 -15.751 -14.731

HSTO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HSTO has a Quality Grade of D, ranking ahead of 11.54% of graded US stocks.
  • HSTO's asset turnover comes in at 0.064 -- ranking 308th of 681 Pharmaceutical Products stocks.
  • PLXP, AGTC, and LPTX are the stocks whose asset turnover ratios are most correlated with HSTO.

The table below shows HSTO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.064 0.403 -1.400
2021-03-31 0.080 0.385 -2.095
2020-12-31 0.126 0.530 -2.520
2020-09-30 0.062 0.633 -4.218
2020-09-30 0.062 0.633 -4.218
2020-06-30 0.190 0.978 -6.396

HSTO Price Target

For more insight on analysts targets of HSTO, see our HSTO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.00 Average Broker Recommendation 1.25 (Strong Buy)

HSTO Stock Price Chart Interactive Chart >

Price chart for HSTO

HSTO Price/Volume Stats

Current price $1.25 52-week high $9.40
Prev. close $1.20 52-week low $0.76
Day low $1.20 Volume 105,444
Day high $1.28 Avg. volume 1,002,990
50-day MA $1.06 Dividend yield N/A
200-day MA $1.53 Market Cap 5.36M

Histogen Inc. (HSTO) Company Bio

Histogen Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. It offers human multipotent cell conditioned media (CCM); human extracellular matrix (hECM); and hair stimulating complex (HSC). The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. Histogen Inc. is headquartered San Diego, California.

HSTO Latest News Stream

Event/Time News Detail
Loading, please wait...

HSTO Latest Social Stream

Loading social stream, please wait...

View Full HSTO Social Stream

Latest HSTO News From Around the Web

Below are the latest news stories about HISTOGEN INC that investors may wish to consider to help them evaluate HSTO as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The biggest pre-market stock movers for Friday are ready to go as we dive into the latest news for investors this morning!

William White on InvestorPlace | March 17, 2023

Why Is Histogen (HSTO) Stock Up 37% Today?

Histogen (HSTO) stock is rising higher on Friday after getting a patent for CTS-2090 that protects its products through 2040.

William White on InvestorPlace | March 17, 2023

Why Is Diebold Nixdorf (DBD) Stock Down 42% Today?

Diebold Nixdorf (DBD) stock is taking a beating on Friday after the company released its annual shareholder letter for 2022.

William White on InvestorPlace | March 17, 2023

Why Is Sarepta Therapeutics (SRPT) Stock Down 20% Today?

Sarepta Therapeutics (SRPT) stock is sliding lower on Friday after the company announced an advisory committee meeting with the FDA.

William White on InvestorPlace | March 17, 2023

Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use

The Newly Issued Patent is Expected to Provide Protection into 2040 Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that t

Yahoo | March 16, 2023

Read More 'HSTO' Stories Here

HSTO Price Returns

1-mo 23.76%
3-mo 50.60%
6-mo -7.41%
1-year -76.42%
3-year -97.95%
5-year -99.89%
YTD 50.60%
2022 -87.53%
2021 -56.11%
2020 -81.05%
2019 -76.88%
2018 -62.55%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8168 seconds.